Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers

Prenatal Diagnosis

Volumn 33, Issue 1, 2013, Pages 95-101

  Moise, K J ^a,b   Boring, N H ^a,b   O'Shaughnessy, R ^c   Simpson, L L ^d   Wolfe, H M ^e,f   Baxter, J K ^g   Polzin, W ^h   Eddleman, K A ⁱ   Hassan, S S ^j   Skupski, D ^k   Mclennan, G ^l   Paladino, T ^l   Oeth, P ^l   Bombard, A ^l,m  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h Tristate Maternal Fetal Medicine Association Inc   (United States)

ⁱ MOUNT SINAI MEDICAL CENTER   (United States)

^j WAYNE STATE UNIVERSITY   (United States)

^k NEW YORK HOSPITAL QUEENS   (United States)

^l SEQUENOM INC   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RHESUS D ANTIBODY;

ADULT; ALLELE; ARTICLE; BASE PAIRING; BLOOD BUFFY COAT; BLOOD SAMPLING; CELL FREE SYSTEM; CONTROLLED STUDY; DATA BASE; DNA DETERMINATION; DNA EXTRACTION; EXON; FEMALE; FETUS; GENE INSERTION; GENE SEQUENCE; GESTATIONAL AGE; HUMAN; MATERNAL BLOOD; PREGNANCY; PRIORITY JOURNAL; PSEUDOGENE; SENSITIVITY AND SPECIFICITY; SEROTYPE; SEX DETERMINATION; VEIN PUNCTURE; Y CHROMOSOME;

BLOOD GROUPING AND CROSSMATCHING; DNA; FEMALE; FETAL BLOOD; GENES, SRY; GENOTYPE; GESTATIONAL AGE; HUMANS; MALE; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM; SENSITIVITY AND SPECIFICITY; SEX DETERMINATION ANALYSIS;

EID: 84872159213     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4018     Document Type: Article

References (22)

1. Liley AW. Liquor amnii analysis in the management of pregnancy complicated by rhesus sensitization. Am J Obstet Gynecol 1961;82:1359-70.
2. Weiner CP, Williamson RA, Wenstrom KD, et al. Management of fetal hemolytic disease by cordocentesis. I. Prediction of fetal anemia [see comments]. Am J Obstet Gynecol 1991;165:546-53.
3. Cherif-Zahar B, Mattei MG, Le Van Kim C, et al. Localization of the human Rh blood group gene structure to chromosome region 1p34.3-1p36.1 by in situ hybridization. Hum Genet 1991;86:398-400.
4. Bennett PR, Le Van Kim C, Colin Y, et al. Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med 1993;329:607-10.
5. Lo YM, Noakes L, Bowell PJ, et al. Detection of fetal RhD sequence from peripheral blood of sensitized RhD- negative pregnant women. Br J Haematol 1994;87:658-60.
6. Bianchi DW, Avent ND, Costa JM, et al. Noninvasive Prenatal Diagnosis of Fetal Rhesus D: Ready for Prime(r) Time. Obstet Gynecol 2005;106:841-4.
7. Queenan JT. Noninvasive fetal rh genotyping: the time has come. Obstet Gynecol 2005;106:682-3.
8. Akolekar R, Farkas DH, VanAgtmael AL, et al. Fetal sex determination using circulating cell-free fetal DNA (ccffDNA) at 11 to 13 weeks of gestation. Prenat Diagn 2010;30:918-23.
9. Tynan JA, Mahboubi P, Cagasan LL, et al. Restriction enzyme-mediated enhanced detection of circulating cell-free fetal DNA in maternal plasma. J Mol Diagn 2011;13:382-9.
10. Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012;52:752-8.
11. Wikman AT, Tiblad E, Karlsson A, et al. Noninvasive Single-Exon Fetal RHD Determination in a Routine Screening Program in Early Pregnancy. Obstet Gynecol 2012;120:227-34.
12. Daniels G, Finning K, Martin P, et al. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004;87:225-32.
13. Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype. Blood 2000;95:12-8.
14. Anderson KG, Kaplan H, Lancaster JB. Demographic correlates of paternity confidence and pregnancy outcomes among Albuquerque men. Am J Phys Anthropol 2006;131:560-71.
15. Prevention of RhD alloimmunization. American College of Obstetricians and Gynecologists Practice Bulletin No. 4, 1999.
16. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program. Can Med Assoc J 1978;118:627-30.
17. Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011;11:5.
18. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
19. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010;12:734-40.
20. Garratty G, Glynn SA, McEntire R. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 2004;44:703-6.
21. Bureau USC. Overview of Race and Hispanic Origin: 2010. 2011.
22. Koelewijn JM, de Haas M, Vrijkotte TG, et al. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008;48:1721-9.